Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025
Abpro Holdings, Inc (ABP)
NASDAQ:AMEX Investor Relations:
abpro.com/contact
Company Research
Source: GlobeNewswire
WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases, today announced an oral presentation of preclinical data for ABP-102/CT-P72 at the American Association for Cancer Research? Annual Meeting 2025 (“AACR 2025”) in the New Drugs on the Horizon session. AACR 2025 is taking place April 25-30, at the McCormick Place Convention Center in Chicago. Invited speaker presentation details Title:ABP-102/CT-P72: a novel HER2 x CD3 T cell engager with selective activity for HER2-overexpressing tumors and reduced activity on cells with normal HER2 expression levelsSession:New Drugs on the Horizon: Part 1Session Date:Sunday, April 27, 2025Session Time:1:00 pm to 2:30 pm CDTPresenter:Adam J. Pelzek, Ph.D., Associate Director, AbproAbstract & Data:Embargoed until time of presentation About ABP-102/CT-P72ABP-102/CT-P72 an investig
Show less
Read more
Impact Snapshot
Event Time:
ABP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABP alerts
High impacting Abpro Holdings, Inc news events
Weekly update
A roundup of the hottest topics
ABP
News
- Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers [Yahoo! Finance]Yahoo! Finance
- Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive CancersGlobeNewswire
- Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic ObjectivesGlobeNewswire
- Abpro (NASDAQ:ABP) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Abpro (NASDAQ:ABP) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ABP&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> to aMarketBeat
ABP
Sec Filings
- 12/15/25 - Form 8-K
- 12/9/25 - Form 8-K
- 12/3/25 - Form EFFECT
- ABP's page on the SEC website